drugset / Trial / NCT06514378
Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction
Phase 1
Recruiting
12 enrolled
Instituto De Investigación Sanitaria Puerta De Hierro-Segovia De Arana
Ministerio de Ciencia e Innovación, Spain · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
Lung transplantation is the only therapeutic alternative for more and more patients with respiratory diseases in their most advanced stages. The most limiting factor to achieve long term survival si chronic lung allograft dysfunction, a multifactorial disease without an effective treatment. The immunomodulatory capacity of mesenchymal stem cells enables them to be a potential therapeutic agent for this condition. The objective of this study is to assess the safety of endobronchial administration of allogeneic MSCs in patients with chroniclung allograft dysfunction.
Timeline
- Start
- 2023-09-19
- Primary completion
- 2025-12-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mesenchymal stem cells | Cell therapy | 1e+06 cells/kg | Other |